Lutetium Treatment

It is a targeted treatment method used in neuroendocrine tumours and metastatic prostate cancers, by labelling with a DOTA Peptide and PSMA Lutetium-177 compound. In situations where no response is obtained from other treatments, the aim with these treatments is to stop the spread of the disease and to reduce the tumour burden in the body.